Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Other Financing Activities
Financing cash flows not reported separately.
Actuate Therapeutics IncNASDAQ: ACTU
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns negative
Q1 FY2026 other financing activities was -$527.72K, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$655.32K.
Context
- Other financing activities increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other financing activities holds near -$527.72K or moves back toward the trailing-twelve-month quarterly average of -$163.83K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (302.83K) USD
- Year-over-year change
- +84.3%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (302.83K) | +84.3% |
| FY2024 | 2024-12-31 | (1.93M) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Financing Activities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -61.0% is the 3rd highest of 7, against a peer median of -85.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $9.92M USD | -9.8% | — | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $655.32K USD | -61.0% | — | — |
| LTM Mar 2026 | CHF 413.44K CHF | -102.6% | — | — | |
| LTM Mar 2026 | $217K USD | -79.2% | — | 1.2% | |
| LTM Mar 2026 | $184K USD | -92.4% | — | — | |
| LTM Mar 2026 | $7K USD | — | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| Peer median (excluding ACTU) | — | -85.8% | — | 0.0% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.07K | 423.54K | 2M | 6.05M |
| Change in Working Capital | 1.73M | 2.57M | 1.1M | (3.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 586.26K | 1.29M | (1.5M) | (512.54K) |
| Other Working Capital | 1.15M | 1.28M | 2.6M | (2.53M) |
| Other Non-Cash Items | (20.38K) | 123.46K | 2.35M | 20.25K |
| Operating Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 5.5M | 0 |
| Common Stock Issued | 0 | 0 | 23.96M | 24.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (1.93M) | (302.83K) |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.46M | (17.49M) | 5.68M | 4.52M |
| Free Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.